2026年，药品零售企业将迎来一轮并购与重组。 近日，商务部、国家发展改革委、工业和信息化部、国家卫生健康委等9部门发布《关于促进药品零售 行业高质量发展的意见》(以下简称《意见》)，鼓励药品零售企业依法开展横向并购与重组。 《意见》指出，支持零售药店进行兼并重组。鼓励药品零售企业依法开展横向并购与重组。鼓励各地优 化营商环境，对于被整合的连锁或单体药店，优化《药品经营许可证》申请核发流程。涉及医保资质变 更的，允许原医保资质继续存续和使用，新医保资质正式开通后，注销原医保资质。 药品零售企业是指将购进的药品直接销售给消费者的经营主体，其核心特征是面向终端消费者进行药品 销售。在实际经营中，这类企业最常见的组织形式就是零售药店，包括单体药店和药品零售连锁企业的 门店。零售药店作为药品流通的"最后一公里"，直接连接患者与药品供应，其健康发展关系到公众用药 可及性、价格合理性及服务质量。 三是兼并重组障碍多，整合效率低。药店并购涉及《药品经营许可证》变更、医保资质衔接等复杂流 程。过去，收购后需重新申请许可证，需要耗时数月；医保资质变更期间易出现"空窗期"，购药无法刷 医保，导致患者流失、收入下滑，抑制企业整合意 ...

Core Viewpoint - The joint issuance of the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry" by nine government departments aims to enhance the professional services, health promotion, and emergency supply capabilities of the pharmaceutical retail sector, establishing it as a "health station" to better serve the public's medical and health needs [1]. Group 1: Key Measures - The first key measure is to improve pharmaceutical services by supporting pharmacies to enhance their pharmaceutical service capabilities, optimize the purchasing experience, participate in centralized drug procurement, and build a payment guarantee system, transforming pharmacies from "drug sales terminals" to "health service stations" [2]. - The second measure focuses on innovating health services by expanding the health service functions of retail pharmacies, improving health service experiences, enriching retail pharmacy formats, optimizing product service experiences, and assisting in the upgrade of pharmaceutical products, thereby reinforcing the health service function of retail pharmacies [2]. - The third measure emphasizes strengthening emergency services by enhancing the service capabilities of retail pharmacies in emergency supply and reinforcing public support for emergency drug supply, ensuring drug availability and medication guidance during emergencies [2]. - The fourth measure aims to optimize industry structure by supporting the merger and reorganization of retail pharmacies, encouraging integrated development of wholesale and retail, and optimizing the pharmaceutical marketing system to improve supply chain efficiency [2]. - The fifth measure involves regulating industry order through the development of smart supervision, promoting fair competition in the industry, and strengthening industry self-discipline to maintain market order and promote integrity and healthy development within the industry [2].

Core Viewpoint - The joint issuance of the "Opinions on Promoting High-Quality Development of the Pharmaceutical Retail Industry" by nine departments aims to enhance the industry through 18 measures focusing on mergers and acquisitions, service transformation, and regulatory optimization [1] Group 1: Industry Impact - The "Opinions" are expected to accelerate the outflow of hospital prescriptions, contributing to growth in the pharmaceutical retail sector [1] - The document encourages horizontal mergers and acquisitions among retail pharmaceutical companies, aiming to optimize the business environment and streamline the licensing process for integrated stores [1][2] - The number of pharmacies in China is projected to decline, with a total of 686,426 stores by the end of Q3 2025, marking a reduction of nearly 20,000 stores since Q4 2024 [2] Group 2: Market Opportunities - The rapid exit of small and medium-sized pharmacies creates market opportunities for leading companies to consolidate and expand their market share through mergers and acquisitions [2] - The "Opinions" promote the transformation of pharmacies from mere sales points to health service hubs, providing new growth avenues for listed pharmacies facing revenue stagnation [2] Group 3: Compliance and Management - Regulatory changes are pushing for a shift towards digital and preventive oversight, enhancing compliance advantages for listed pharmacies compared to smaller competitors [3] - Companies like Yifeng Pharmacy have demonstrated significant profit growth through refined management and compliance, with a 10.27% increase in net profit year-on-year for the first three quarters of 2025 [3] - The core competitiveness of retail pharmacies is increasingly seen in their professional capabilities, with companies developing comprehensive pharmaceutical service systems [3][4]

2026.01. 23 该《意见》提出，鼓励行业协会或区域医药流通龙头企业牵头，引导药品零售企业参与药品集中带量 采购。针对其他药品，鼓励零售药店整合采购需求，开展联合采购，实现量价挂钩，提升议价能力。 在医院端，药品的集采已走向常态化发展，但要推动药店参与集采，还面临哪些堵点？ "《意见》的提出，标志着国家层面对药店参与集采的正式认可和推广，支持药店通过省级医药采购 平台采购，并要求生产企业保障供应。此前，国家组织药品集采主要针对医疗机构，这次扩展了药店 的参与路径，旨在提升药店议价能力和供应链效率。"湖南药品流通行业协会原秘书长黄修祥对第一 财经记者说。 为提高患者购药的便利性与可及性，缩小集中带量采购中选药品在医疗机构与零售药店销售的价格差 异，此前也有政策在鼓励药店参与药品集采，甚至个别地区已在探索集采药品在药店落地。总体上 看，药店销售集采药品的积极性有待提高。 黄修祥表示，药店参与集采，可以降低药品采购成本、丰富药品种类并提升服务能力。同时，集釆药 品进药店的话，能够给药店带来一定的客流，药店可以在此基础做一些关联销售。但面临的挑战是， 集采药品需"零差率"销售（无加成），这导致药店的利润空间大幅 ...

Core Viewpoint - The Ministry of Commerce and nine other departments have issued the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry," proposing 18 measures to enhance the professional, intensive, digital, and standardized development of the pharmaceutical retail sector [1][10]. Group 1: Industry Growth and Transformation - The pharmaceutical circulation market in China is expected to grow from 24.1 trillion yuan in 2020 to 29.5 trillion yuan in 2024, representing a 22.4% increase, with the retail market projected to reach 650 billion yuan by 2024 [1]. - The industry is undergoing a critical transformation from traditional drug sales to comprehensive health services, aiming to become community-oriented "health stations" that enhance the resilience and accessibility of the national health security system [1][10]. Group 2: Challenges and Pain Points - Current challenges in the pharmaceutical retail sector include a shortage of licensed pharmacists, inadequate prescription review processes, restrictions on online prescription sales, and obstacles in medical insurance reimbursement [1][2]. - The lack of quality control and service capabilities in retail pharmacies, along with the need for improved supporting policies, are significant issues that the new document aims to address [2]. Group 3: Policy Measures and Recommendations - The "Opinions" encourage the enhancement of pharmaceutical service capabilities by promoting the establishment of pharmacist teams and health consultants in retail pharmacies, as well as allowing remote prescription reviews by registered pharmacists [4]. - The document supports the optimization of the purchasing experience, participation in centralized drug procurement, and the establishment of payment security systems to facilitate the transition from "drug sales terminals" to "health service stations" [4]. Group 4: Industry Structure and Integration - The "Opinions" advocate for the restructuring of the industry by encouraging mergers and acquisitions among retail pharmacies to improve operational efficiency and quality control [6][7]. - The document highlights the importance of integrating wholesale and retail operations to enhance supply chain efficiency and reduce operational costs [7]. Group 5: Regulatory and Digital Transformation - The "Opinions" propose the development of smart regulation to ensure accurate tracking and verification of drug traceability codes, transitioning to a service-oriented and preventive regulatory model [8][9]. - The document emphasizes the need for a unified digital transformation strategy across the industry, as current efforts are fragmented and lack government coordination [9]. Group 6: Emergency Services and Public Health - The "Opinions" call for strengthening the emergency supply capabilities of retail pharmacies and enhancing public support for drug supply during emergencies [9][10]. - Overall, the document aims to address the industry's challenges and improve the accessibility and quality of health services for the public [10].

Core Viewpoint - The enthusiasm of pharmacies to participate in drug centralized procurement needs to be improved, despite the government's push for their involvement [1][3]. Group 1: Government Initiatives - On January 22, the Ministry of Commerce and nine other departments issued an opinion to promote high-quality development in the drug retail industry, encouraging pharmacies to participate in centralized procurement [2]. - The opinion aims to enhance the bargaining power of pharmacies and improve supply chain efficiency by allowing them to procure through provincial medical procurement platforms [3]. Group 2: Challenges Faced by Pharmacies - Pharmacies face significant challenges in participating in centralized procurement, including the requirement for "zero markup" sales, which compresses profit margins and may lead to unprofitable operations [4]. - The lack of significant increases in prescriptions flowing from hospitals to pharmacies further restricts their willingness to engage in centralized procurement [4]. Group 3: Recommendations for Improvement - To enhance pharmacy participation, it is essential to improve the prescription flow mechanism and optimize the settlement methods for medical insurance funds, potentially reducing settlement periods from quarterly to monthly [4]. - The government should establish a robust prescription flow mechanism and improve communication channels among stakeholders to address supply shortages and ensure timely delivery of drugs [5].

Core Viewpoint - The document outlines a set of opinions aimed at promoting the high-quality development of the pharmaceutical retail industry, focusing on optimizing services and payment methods for insured individuals purchasing medications at designated retail pharmacies [1] Group 1: Policy Enhancements - The opinions propose optimizing outpatient comprehensive services at designated retail pharmacies, allowing insured individuals to purchase medications listed in the medical insurance catalog using prescriptions from designated medical institutions, with costs covered by the insurance fund as per regulations [1] - It supports the use of employee medical insurance personal accounts to pay for out-of-pocket medical expenses incurred by insured individuals and their eligible relatives when purchasing medications at designated retail pharmacies [1] Group 2: Efficiency Improvements - The document emphasizes the need to optimize the settlement methods between the medical insurance fund and retail pharmacies, aiming to effectively reduce settlement times and enhance efficiency [1] - It also calls for the optimization of resource allocation for designated retail pharmacies, aligning with the construction of convenient living circles, to promote a reasonable layout of these pharmacies [1]

Investment Rating - The industry is rated as "Neutral" [8][60] - Specific company ratings include "Buy" for 恒瑞医药 (Hengrui Medicine) and "Increase" for 药明康德 (WuXi AppTec) [8][60] Core Insights - The report highlights the issuance of opinions by nine departments, including the Ministry of Commerce, aimed at promoting high-quality development in the pharmaceutical retail industry, indicating a potential turning point for pharmacy operations [8][16] - The report emphasizes the expected benefits for leading chain pharmacies from policy support and increased industry concentration [8][16] - The inclusion of the drug替尔泊肽 (Tirzepatide) as a breakthrough therapy for treating metabolic-associated fatty liver disease is noted as a significant development [8][16] Industry News - The National Medical Insurance Administration issued a guideline for the pricing of surgical and treatment auxiliary services, consolidating existing price projects into 37 items [16] - The report discusses the promotion of pharmaceutical retail industry transformation towards a "health service hub" through enhanced pharmacy services and optimized purchasing experiences [16][17] - The report mentions the ongoing development of AI applications in healthcare and pharmaceuticals, suggesting investment opportunities in AI-related companies [8][58] Industry Data - As of January 22, 2026, the price index for traditional Chinese medicine shows a year-on-year decline of 14%, with specific herbs like 连翘 (Forsythia) and 党参 (Codonopsis) experiencing significant price drops of 31% and 36% respectively [18][23] - The SW pharmaceutical industry’s price-to-earnings ratio (TTM) is reported at 52.01 times, with a valuation premium of 266% relative to the CSI 300 index [52] Company Announcements - 恒瑞医药 (Hengrui Medicine) received clinical trial approval for multiple drugs, including SHR-7787 and 阿得贝利 (Adalimumab) [30] - 百利天恒 (Baili Tianheng) has had its drug application for treating recurrent or metastatic esophageal squamous cell carcinoma accepted [31] - 复星医药 (Fosun Pharma) announced plans to spin off a subsidiary for listing and received clinical trial approval for a drug targeting advanced colorectal cancer [35]

Investment Rating - The industry investment rating is "Leading the Market" [2][5]. Core Viewpoints - The report emphasizes that the pharmaceutical retail industry is entering a phase of high-quality development, supported by government policies aimed at promoting the sector [5]. - Key initiatives include accelerating the outflow of prescriptions, enhancing industry concentration, and fostering innovation in health services, which are expected to benefit leading retail pharmacies [5]. - The report suggests that leading retail pharmacies are well-positioned to capitalize on these trends due to their strong compliance, refined management capabilities, and financial health [6]. Summary by Relevant Sections Industry Overview - The pharmaceutical retail sector is recognized as a crucial part of the national healthcare system, with a focus on enhancing professional services and emergency supply capabilities [5]. - The report outlines 18 development measures across five areas: improving pharmaceutical services, innovating health services, strengthening emergency services, optimizing industry structure, and regulating industry order [5]. Market Dynamics - The report indicates that the outflow of hospital prescriptions will contribute to growth in the pharmaceutical retail sector, with measures to enhance the efficiency of electronic prescription platforms [5]. - It highlights the encouragement of horizontal mergers and acquisitions among retail pharmacies to increase industry concentration and streamline operations [5]. Future Outlook - The report anticipates that with ongoing consumer promotion policies and a gradual reduction in regulatory impacts, leading retail pharmacies will see improved operational performance [6]. - It recommends focusing on leading retail pharmacies with strong management capabilities, compliance, and advantageous locations, such as Yifeng Pharmacy [6].

Core Viewpoint - The article highlights the strong performance of the space photovoltaic and space tourism sectors, leading to significant gains in related stocks and a notable rise in the commercial aerospace sector [2][4]. Group 1: Space Photovoltaic Sector - The space photovoltaic concept showed stronger performance, driving a broad increase in the photovoltaic sector, including photovoltaic equipment, BC batteries, and POE films [4]. - Space solar power technology collects solar energy in space via satellites and transmits it to the ground in the form of microwaves or lasers, achieving a conversion efficiency that is 2-3 times higher than that on Earth due to continuous sunlight availability in geostationary orbit [7]. - The efficiency of solar energy in space is approximately 1367 W/m², which is over 30% higher than the ground standard of 1000 W/m², significantly enhancing photovoltaic cell output [7]. Group 2: Space Tourism Sector - The "Chuan Yue Zhe" manned spacecraft was publicly showcased, with over 20 space tourists already booked for future flights, aiming for a manned launch by 2028 [8]. - The successful verification of the landing buffer system for the spacecraft marks "Chuan Yue Zhe" as the third commercial aerospace company globally to develop and validate such technology [8]. Group 3: Pharmaceutical Sector - Pharmaceutical stocks saw an increase, with significant gains in sectors such as pharmaceutical commerce, family doctors, medical services, and innovative drugs [10]. - A new policy document aimed at promoting high-quality development in the pharmaceutical retail industry was released, proposing 18 measures to enhance service quality and market vitality [12]. - Leading companies in the pharmaceutical sector are expected to benefit from ongoing policy support, with opportunities for market share growth and diversification into non-pharmaceutical products [12].